Shares of Brand Engagement Network (BNAI) more than doubled on December 29 after the conversational artificial intelligence (AI) solutions company landed a sizable contract from a leading advertising agency.
In its press release, BNAI confirmed that it will develop a custom AI engagement solution for one of the agency’s clients, which is a top 10 pharmaceutical company.
Despite the cosmic streak, Brand Engagement Network stock is still down about 75% year to date.
BNAI shares soared following the deal announcement primarily because it represents significant near-term revenue for the microcap company.
Management expects the deal to generate $250,000 in development revenue in the final quarter of this year, with recurring monthly license fees expected to reach 2026.
More broadly, the deal demonstrates Brand Engagement Network’s ability to penetrate regulated and high-barrier industries where AI compliance and data integrity are paramount concerns.
In short, the strategic entry into the pharmaceutical space represents important commercial validation for the company’s technology platform, making its stock much more attractive in the coming year.
Investors should note that Brand Engagement Network, even after an explosive rally this week, is still a penny stock, which often means extreme volatility and higher ownership risk.
On the other hand, however, BNAI technical data suggests that the momentum will continue. The recent rally has taken it beyond its 61.8% Fibonacci retracement level, potentially clearing the path towards $10.
Furthermore, the stock’s 9-day Relative Strength Index (RSI) currently stands at 49, reinforcing that it could continue to rise without reaching overbought conditions.
BNAI stock is worth owning too because the company’s broader AI healthcare strategy extends beyond a single contract, to an exclusive licensing partnership in Latin America and the planned launch of Skye Salud in Mexico.
Brands Engagement Network Inc is currently not covered by a large number of Wall Street analysts.
